Evidence map›Paper›PMID 31500514›Full record

ArticlemAbs

High sensitivity LC-MS profiling of antibody-drug conjugates with difluoroacetic acid ion pairing.

Jennifer M Nguyen, Jacquelynn Smith, Susan Rzewuski, Cristina Legido-Quigley, Matthew A Lauber

Open access · goldAbstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Jennifer M NguyenSchool of Science, University of Copenhagen , Frederiksberg , Denmark.ORCID 0000-0002-3864-0009
Jacquelynn SmithBioTherapeutics Pharmaceuticial Sciencies, Pfizer, Inc ., Chesterfield , MO , USA.
Susan RzewuskiChemistry Technology Center, Waters Corporation , Milford , MA , USA.ORCID 0000-0002-4140-5675
Cristina Legido-QuigleySystems Medicine, Steno Diabetes Center , Gentofte , Denmark.
Matthew A LauberChemistry Technology Center, Waters Corporation , Milford , MA , USA.ORCID 0000-0003-0929-903X
Waters (United States) · USPfizer (United States) · USSteno Diabetes Centers · DKUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reversed-phase liquid chromatography (RPLC) separations of proteins using optical detection generally use trifluoroacetic acid (TFA) because it is a strong, hydrophobic acid and a very effective ion-pairing agent for minimizing chromatographic secondary interactions. Conversely and in order to avoid ion suppression, analyses entailing mass spectrometry (MS) detection is often performed with a weaker ion-pairing modifier, like formic acid (FA), but resolution quality may be reduced. To gain both the chromatographic advantages of TFA and the enhanced MS sensitivity of FA, we explored the use of an alternative acid, difluoroacetic acid (DFA). This acid modifier is less acidic and less hydrophobic than TFA and is believed to advantageously affect the surface tension of electrospray droplets. Thus, it is possible to increase MS sensitivity threefold by replacing TFA with DFA. Moreover, we have observed DFA ion pairing to concomitantly produce higher chromatographic resolution than FA and even TFA. For this reason, we prepared and used MS-quality DFA in place of FA and TFA in separations involving IdeS digested, reduced NIST mAb and a proprietary antibody-drug conjugate (ADC), aiming to increase sensitivity, resolution and protein recovery. The resulting method using DFA was qualified and applied to two other ADCs and gave heightened sensitivity, resolution and protein recovery versus analyses using TFA. This new method, based on a purified, trace metal free DFA, can potentially become a state-of-the-art liquid chromatography-MS technique for the deep characterization of ADCs.

Indexed as

Tandem Mass SpectrometryAntibodies, MonoclonalChromatography, Reverse-PhaseHydrophobic and Hydrophilic InteractionsImmunoconjugatesAntibodies, MonoclonalImmunoconjugatesADCantibody-drug conjugateDARDFADifluoroacetic aciddisulfide isoformsdrug-to-antibody ratioFAformic acidIdeS digestionLC-MSmAbmetal adductsmonoclonal antibodyMS sensitivityNIST mAbpeak capacitypotassiumprotein recoveryreversed-phase chromatographysalt adductssodiumsubunit profilingTFAtrifluoroacetic acid

Identifiers

PMID31500514
PMCPMC6816370
OpenAlexW2973084361

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.